Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6633029 | 0.82 | ALDH1A1 (0.42) | ALDH1A1HCAR2LMNACES2CES1 | |
| SCHEMBL9616640 | 0.77 | MAPT (0.41) | ALDH1A1HCAR2LMNATP53HTT | |
| SCHEMBL8015875 | 0.73 | ALDH1A1 (0.38) | ALDH1A1HCAR2LMNATP53HTT | |
| SCHEMBL7383033 | 0.69 | ALDH1A1 (0.44) | ALDH1A1HCAR2LMNATP53HTT | |
| Potassium Ion SCHEMBL11295824 | 0.67 | AKR1C1 (0.38) | LMNAHTTKMT2AHDAC1HDAC2 | |
| SCHEMBL20505064 | 0.64 | OPRM1 (0.45) | ALDH1A1HCAR2TP53HTTKMT2A | |
| SCHEMBL2795442 | 0.63 | ALDH1A1 (0.51) | ALDH1A1LMNATP53HTTMAPT | |
| SCHEMBL754463 | 0.62 | SLC6A3 (0.41) | HCAR2LMNAKMT2A | |
| SCHEMBL30243505 | 0.62 | ALDH1A1 (0.47) | ALDH1A1LMNATP53HTTMAPT | |
| SCHEMBL11283171 | 0.62 | OPRM1 (0.49) | ALDH1A1HCAR2TP53HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190502-A1 | PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SANDOZ AG (CH) | 2011-08-04 | — | — | US | disclosed |
| EP-2346879-A1 | A PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | Sandoz AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010046476-A1 | A PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SANDOZ AG (CH) | 2010-04-29 | — | — | WO | disclosed |
| EP-2168969-A2 | Racemization and Enantiomer Separation of Clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-31 | — | — | EP | disclosed |
| EP-1483269-B1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMA (IL) | 2009-10-14 | — | — | EP | disclosed |
| US-7446200-B2 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV, LTD. (IN) | 2008-11-04 | — | — | US | disclosed |
| WO-2007144729-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CLOPIDOGREL | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-12-21 | — | — | WO | disclosed |
| EP-1848720-A1 | RAPID RESOLUTION PROCESS FOR CLOPIDOGREL BASE AND A PROCESS FOR PREPARATION OF CLOPIDOGREL BISULFATE POLYMORPH - FORM I | USV LIMITED (IN) | 2007-10-31 | — | — | EP | disclosed |
| US-7259261-B2 | Racemization and enantiomer separation of clopidogrel | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) | 2007-08-21 | — | — | US | disclosed |
| WO-2006087729-A1 | RAPID RESOLUTION PROCESS FOR CLOPIDOGREL BASE AND A PROCESS FOR PREPARATION OF CLOPIDOGREL BISULFATE POLYMORPH - FORM I | USV LIMITED (IN) | 2006-08-24 | — | — | WO | disclosed |
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV LIMITED (IN) | 2006-04-06 | — | — | US | disclosed |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | ENTIRE INTEREST | 2005-03-03 | — | — | US | disclosed |
| EP-1483269-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | Teva Pharmaceutical Industries Limited (IL) | 2004-12-08 | — | — | EP | disclosed |
| US-6800759-B2 | REACTING MIXTURE OF (R) AND (S) CLOPIDOGREL FREE BASE WITH LEVOROTATORY CAMPHORSULFONIC ACID IN C5 TO C12 HYDROCARBON TO PRECIPITATE (S) CLOPIDOGREL CAMPHORSULFONATE, CONVERTING TO FREE BASE, PRECIPITATING CLOPIDOGREL BISULFATE IN SOLVENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-05 | — | — | US | disclosed |
| US-6737411-B2 | CRYSTALLIZING AS CAMPHOR SULFONATE SALT; CONVERTING PURIFIED MATERIAL BACK TO FREE BASE FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2004013147-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-05 | — | — | US | disclosed |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICALS USA, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6080875-A | REACTING A THIENYLGLYCIDIC DERIVATIVE WITH A PHENYLGLYCINE ESTER IN THE PRESENCE OF AN ALKALI METAL BOROHYDRIDE, DECYCLIZATION; PREPARING DRUGS FOR TREATING ANTI-PLATELET AGGREGATION AND ANTITHROMBOTIC ACTIVITIES | SANOFI-SYNTHELABO (FR) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | SRR, P2RY11, CYP2C19 | ALDH1A1 362/4885HCAR2 694/4885LMNA 3209/4885 |
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885HCAR2 791/4885LMNA 4323/4885 |
| US-20110190502-A1 | PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL | SRR, P2RY13, P2RY11 | ALDH1A1 1320/4885HCAR2 481/4885LMNA 3333/4885 |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885HCAR2 791/4885LMNA 4323/4885 |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | ALDH1A1 1422/4885HCAR2 791/4885LMNA 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.